BioSpace News Archive

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Design Therapeutics, Inc., a biotechnology company developing treatments for serious degenerative genetic diseases, announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.

KalVista Pharmaceuticals, Inc. announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Promising Innovative Medicine designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Pfizer Inc. announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma showed a statistically significant and clinically meaningful improvement in overall survival compared to lenalidomide and rituximab plus placebo.

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support.

908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia.

Arecor Therapeutics plc and TRx Biosciences Limited announced a research collaboration for the formulation development of an oral glucagon-like peptide-1 receptor agonist product.

Gossamer Bio, Inc. announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors.

MaaT Pharma will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients.